Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (367)	8/11/2000 6:21:45 PM
From: Vector1	Read Replies (1) \| Respond to of 496

Tuck, Apparently the phase I was in healthy volunteers. They obviously spent time working out max safe dose and learned a lot about side effects. The only thing I have seen regarding efficacy is that they confirmed that the compound crossed the blood brain barrier in humans. Obviously one of the critical elements for an orally available drug. Remember, AMGN held back on initiating the phase I waiting for a next generation and more powerful compound. Although not a stockholder I have great respect for AMGN. They are fairly conservative and know how to run a trial. The market is huge and I like the play long term. V1